AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27978771
Drug: Retention strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retention strategies in buprenorphine treatment
Trial: 15743000
Drug: Probiotics (fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (fermented milk product Cultura containing live lactobacilli (La-5) and bifidobacteria (Bb-12), 500 ml daily for 4 weeks)
Trial: 9040746
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of recombinant human NGF (1 or 3 micrograms)
Trial: 30245328
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg prednisolone
Trial: 21384133
Drug: Irbesartan 300,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300, 600, and 900 mg o.d. for 2 months each
Trial: 17627404
Drug: Milk supplement
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplement (two sachets of milk powder containing 1000 mg calcium and 80 microg vitamin K(1)) for 24 months
Trial: 16135347
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of continuous femoral and sciatic nerve block (FEM/SCI)
Trial: 14535870
Drug: Propranolol (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (oral, n=12)
Trial: 14535870
Drug: Lanreotide SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide SR (intramuscular, 30 mg once weekly, n=12)
Trial: 11152019
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with delavirdine, zidovudine and lamivudine, didanosine or zalcitabine for 1 year
Trial: 11152019
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with delavirdine
Trial: 11152019
Drug: Dual NRTI
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual NRTI therapy (delavirdine plus zidovudine or 2 NRTIs)
Trial: 11152019
Drug: Delavirdine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine as a component of protease inhibitor‐containing regimens
Trial: 11152019
Drug: Delavirdine-containing combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine-containing combination therapy
Trial: 11152019
Drug: Delavirdine-containing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine-containing treatment
Trial: 11152019
Drug: Delavirdine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine as a first‐line therapy with 2 NRTIs
Trial: 8967600
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nitrous oxide and enflurane
Trial: 2426934
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (5000 IU bolus followed by 830 IU/hr for 2 hours)
Trial: 2426934
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (5000 IU bolus)
Trial: 17227525
Drug: Neostigmine 0.5
RxNorm normalized name: neostigmine 0.5 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.5 mg IV
Trial: 12374900
Drug: Imidapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (5 to 10 mg per day)
Trial: 12374900
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 to 50 mg twice per day)
Trial: 9825268
Drug: Furosemide infusion
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide infusion (2 x 40 mg)
Trial: 9825268
Drug: Furosemide bolus
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide bolus injection (2 x 40 mg)
Trial: 9825268
Drug: Furosemide infusion
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide infusion
Trial: 9825268
Drug: Furosemide bolus
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide bolus injection
Trial: 8120709
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (8 gm daily, containing 3.2 gm eicosapentaenoic acid and 2.2 gm docosahexaenoic acid)
Trial: 990700
Drug: Elemental diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental diet as preoperative bowel preparation
Trial: 990700
Drug: Routine bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine bowel preparation
Trial: 24824660
Drug: D-Cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (DCS) administered at a dosage of 50 mg either once weekly or daily for 8 weeks.
Trial: 24824660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified in detail, but implied to be a placebo or no treatment).
Trial: 18678823
Drug: DHEA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 100 mg/d
Trial: 18678823
Drug: DHEA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 400 mg/d
Trial: 10084491
Drug: Positional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positional treatment
Trial: 525733
Drug: Domperidone given
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone given prophylactically with morphine
Trial: 1915517
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose salicylate (100 mg/kg per day)
Trial: 1915517
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose salicylate (30 mg/kg per day)
Trial: 29027116
Drug: Intracoronary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary and intravenous melatonin (total 50 mg)
Trial: 23928707
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration group (ropivacaine 0.2% infusion)
Trial: 23928707
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration group (ropivacaine 0.1% infusion)
Trial: 23928707
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion group (saline 0.9% infusion)
Trial: 21305734
Drug: PreOp group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PreOp group (carbohydrate drink 200 mL two hours before surgery)
Trial: 12037148
Drug: hOKT3gamma1(Ala‐Ala) monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment for 14 days
Trial: 12037148
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibody treatment)
Trial: 12037148
Drug: hOKT3gamma1(Ala‐Ala) monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment
Trial: 26857829
Drug: Multicomponent sun
RxNorm normalized name: CLOZAPINE (SUN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent sun protection program (read-along book, swim shirt, weekly text-message reminders)
Trial: 24534682
Drug: Multi-media tablet
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-media tablet device delivering graphic and verbal information
Trial: 16083521
Drug: Trazodone prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone prolonged release 150-450 mg/day (n = 55)
Trial: 16083521
Drug: Paroxetine 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-40 mg/day (n = 53)
Trial: 12404164
Drug: Repeated treatment
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated treatment with praziquantel
Trial: 12404164
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (children who did not receive chemotherapy)
Trial: 10594405
Drug: L-Arginine (L-Arg)
RxNorm normalized name: L-Arg
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (L-Arg)
Trial: 10594405
Drug: L-NMMA +
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA + L-Arg
Trial: 8677930
Drug: 125-mg 13C
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 125-mg 13C urea breath test at 30 min
Trial: 8677930
Drug: 250-mg 13C
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250-mg 13C urea breath test at 40 min
Trial: 8677930
Drug: 125-mg 13C
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 125-mg 13C urea breath test
Trial: 1961376
Drug: Azathioprine (Germed)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (Germed) 50 or 75 mg daily depending on body weight, treatment stopped after two months for one month
Trial: 1961376
Drug: Prednisone (Encorton,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (Encorton, Polfa) 5 or 10 mg daily
Trial: 26971745
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shockwave therapy (rESWT) - 0.340 mJ/mm2, 2000 shots
Trial: 19089890
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg twice per day + Vaginal conjugated equine estrogen 0.625 mg twice a week
Trial: 19089890
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg twice per day
Trial: 11430419
Drug: Standard-dose lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose lenograstim (263 microg/day)
Trial: 11430419
Drug: Low-dose lenograstim
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lenograstim (131.5 microg/day)
Trial: 2635871
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg suppositories twice daily)
Trial: 2635871
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo suppositories)
Trial: 415870
Drug: 4-methylpyrazole (4-MP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-methylpyrazole (4-MP, 7 mg/kg body wt i.v.)
Trial: 415870
Drug: Ethanol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.6 g/kg body wt)
Trial: 26164096
Drug: Treatment including
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment including doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg + doxorubicin 50 mg/m² every 6 weeks)
Trial: 26164096
Drug: Treatment excluding
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment excluding doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg)
Trial: 24166522
Drug: G‐CSF 1‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 1‐6 cycles
Trial: 24166522
Drug: G‐CSF 1‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 1‐2 cycles
Trial: 24166522
Drug: G‐CSF 1‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 1‐6 cycles vs G‐CSF 1‐2 cycles
Trial: 19476724
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control group (standard treatment with nurse feedback)
Trial: 17708161
Drug: HyperHaes solution
RxNorm normalized name: Hyperhep B Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperHaes solution (250ml 7.2% NaCl/6% HES solution)
Trial: 17708161
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate (500 ml Ringer's acetate solution)
Trial: 11521723
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab (Herceptin)
Trial: 3285731
Drug: Diazepam po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam po (0.1 mg.kg‐1)
Trial: 25111236
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of an angiotensin I-converting enzyme inhibitor and angiotensin II-receptor blocker
Trial: 25111236
Drug: Angiotensin I-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin I-converting enzyme inhibitor alone
Trial: 21954530
Drug: T-piece (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-piece (4 L/min)
Trial: 19700946
Drug: Brief psychosocial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychosocial therapy (BPST) for 4 weeks
Trial: 15324466
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg) alone
Trial: 15324466
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg) plus Ivermectin (200 microg/kg)
Trial: 15324466
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg) plus Albendazole (400 mg)
Trial: 11153551
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2 microg/kg) 5 min before MH placement
Trial: 11153551
Drug: Local lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local lidocaine infiltration (3 ml 1% plain lidocaine) at each pin site 1 min before MH placement
Trial: 11153551
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl + local lidocaine infiltration
Trial: 9342546
Drug: 37/40 kD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37/40 kD antibodies in Type 1a diabetic patients
Trial: 9342546
Drug: 37/40 kD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37/40 kD antibodies in Type 1b diabetic patients
Trial: 9342546
Drug: GAD antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibodies and/or 37/40 kD antibodies
Trial: 9342546
Drug: GAD antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibodies in schoolchildren
Trial: 9342546
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ICA with at least two other markers in relatives
Trial: 9342546
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of multiple antibodies in ICA-positive non-diabetic subjects
Trial: 1547194
Drug: niacin/colestipol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/colestipol plus diet therapy
Trial: 22607563
Drug: Oral mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mercaptopurine (0.5 mg/kg per day)
Trial: 21135366
Drug: ICD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD with appropriate therapy
Trial: 21135366
Drug: ICD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD with no appropriate therapy
Trial: 21135366
Drug: ICD shock
RxNorm normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICD shock therapy
Trial: 21135366
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (Control, n=342)
Trial: 17624213
Drug: Ginseng supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng supplementation (3 grams of 100% ginseng orally daily for 8 weeks)
Trial: 17624213
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose powder, same dosage and duration as ginseng)
Trial: 15903359
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (6 g of creatine monohydrate per day)
Trial: 9523367
Drug: Fenoterol inhalation
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol inhalation
Trial: 11050693
Drug: EPI-10 (glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI-10 (glyceryl trinitrate transdermal patch)
Trial: 11050693
Drug: ND-10 (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND-10 (reference patch)
Trial: 9282973
Drug: Age effect
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age effect on marker excretion
Trial: 3576660
Drug: Chewable tablet
RxNorm normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablet formulation
Trial: 27006510
Drug: Standard glycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycemic treatment (Control)
Trial: 24736279
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of telmisartan
Trial: 22344551
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg exenatide single dose
Trial: 22344551
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg exenatide single dose
Trial: 22344551
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg exenatide multiple doses
Trial: 22344551
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg exenatide multiple doses
Trial: 22344551
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events after 5 μg exenatide
Trial: 22344551
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events after 10 μg exenatide
Trial: 10940515
Drug: Human natural
RxNorm normalized name: Human natural killer-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human natural leucocytic interferon (HNLI) applied locally at 2x10(6) U daily in pessaries for 21 days before surgery
Trial: 10940515
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with HNLI)
Trial: 9263140
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (MTX) plus prednisone > or = 5 mg/day
Trial: 9263140
Drug: Prednisone >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone > or = 5 mg/day without MTX
Trial: 9263140
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (MTX)
Trial: 3545273
Drug: (‐)‐adrenaline (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (‐)‐adrenaline (0.06 microgram kg‐1 min‐1 for 90 min) + vehicle control (+)‐glucose infusion (60 min)
Trial: 3545273
Drug: salbutamol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol (120 ng kg‐1 min‐1 for 30 min) + vehicle control (+)‐glucose infusion (90 min)
Trial: 3545273
Drug: vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle control (+)‐glucose infusion
Trial: 24183837
Drug: eGFR 20-44
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR 20-44 mL/min/1.73m(2)
Trial: 24183837
Drug: eGFR >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR > 60 mL/min/1.73m(2)
Trial: 24183837
Drug: eGFR <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR < 60 mL/min/1.73m(2)
Trial: 22526314
Drug: Polymorph form
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorph form I of ST-246, 400 mg oral dose
Trial: 22526314
Drug: Polymorph form
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorph form V of ST-246, 400 mg oral dose